Verition Fund Management
OCUL icon

Verition Fund Management’s Ocular Therapeutix OCUL Stock Holding History

Verition Fund Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Sell
299,199
-228,139
-43% -$2.07M 0.01% 916
2026
Q1 		$4.47M Buy
527,338
+355,732
+207% +$3.39M 0.03% 631
2025
Q4 		$2.08M Buy
171,606
+5,573
+3% +$67.7K 0.01% 1580
2025
Q3 		$1.94M Buy
166,033
+17,431
+12% +$208K 0.01% 2010
2025
Q2 		$1.38M Buy
148,602
+78,172
+111% +$612K 0.01% 2228
2025
Q1 		$516K Buy
+70,430
New +$541K ﹤0.01% 2571
2024
Q4 		– Sell
-62,501
Closed -$544K – 3434
2024
Q3 		$544K Buy
+62,501
New +$515K ﹤0.01% 2268
2023
Q3 		– Sell
-54,950
Closed -$284K – 2578
2023
Q2 		$284K Buy
+54,950
New +$327K ﹤0.01% 1597
2023
Q1 		– Sell
-17,502
Closed -$49.2K – 2443
2022
Q4 		$49.2K Buy
17,502
+7,273
+71% +$24.1K ﹤0.01% 1890
2022
Q3 		$42K Hold
10,229
– – ﹤0.01% 2705
2022
Q2 		$41K Buy
10,229
+229
+2% +$865 ﹤0.01% 2169
2022
Q1 		$50K Hold
10,000
– – ﹤0.01% 2489
2021
Q4 		$70K Buy
+10,000
New +$77.7K ﹤0.01% 2378

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Verition Fund Management's OCUL Position: Q2 2026 in Review

Verition Fund Management reduced its Ocular Therapeutix (OCUL) stake by 43% in Q2 2026, selling an estimated $2.07M and leaving 299,199 shares worth $2.94M. The position accounts for 0.01% of the portfolio, ranked #916.

Verition Fund Management first reported a position in OCUL in Q4 2021 and has held it in 13 quarters since. The position peaked at $4.47M in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Verition Fund Management held 299,199 shares of Ocular Therapeutix worth $2.94M as of Q2 2026.
  • Verition Fund Management sold 228,139 Ocular Therapeutix shares in Q2 2026, an estimated $2.07M.
  • Ocular Therapeutix made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #916 holding.
  • Verition Fund Management first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 13 quarters since.
  • Verition Fund Management's Ocular Therapeutix position peaked at $4.47M in Q1 2026.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.